Abstract:Background: Down-Regulated in Adenoma (DRA) plays a critical role in intestinal chloride absorption and a decrease in its expression is a key event in diarrheal disorders. Recently, DRA has emerged as an Inflammatory Bowel Disease (IBD) susceptibility gene. Therefore, the strategies to upregulate DRA expression are potentially novel approaches to not only treat IBD-associated diarrhea but also gut inflammation. In this study, the effect of dexamethasone (DEX), an anti-inflammatory corticosteroid on DRA expression was investigated. Methods: GR (glucocorticoid receptor) overexpressed Caco-2 cells and C57BL/6/J mice and anti-αIL-10R mAb model of IBD were used. Protein expression was assessed by immunoblotting and immunofluorescence. Transcript levels were assessed by quantative-real-time polymerase chain reaction (qRT-PCR) and promoter activity was measured by luciferase assays. Results: Our results showed that DEX significantly increased DRA mRNA and protein expression in GR overexpressing Caco-2 cells. DEX-induced upregulation of DRA was GR dependent and appeared at least in part to occur via a transcriptional mechanism, as promoter activity of the DRA construct (-1183/+114 bp) was significantly increased in response to DEX. The increase in DRA mRNA was abrogated in the presence of MKP-1 inhibitor, triptolide. Administration of DEX (2 mg/kg body weight) to mice for 24 and 48 hours significantly increased the DRA expression in mouse colon. DEX treatment to mice for 7 days in the αIL-10R mAb model of colitis was able to significantly attenuate the gut inflammation and associated decrease in DRA expression. Conclusions: We demonstrate that DEX stimulates DRA expression via transcriptional mechanisms and suggest that upregulation of DRA may contribute to both anti-inflammatory and pro-absorptive effects of DEX.

Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats

Semi-quantitative Profiling of Bile Acids in Serum and Liver Reveals the Dosage-Related Effects of Dexamethasone on Bile Acid Metabolism in Mice

The effects, underlying mechanism and interactions of dexamethasone exposure during pregnancy on maternal bile acid metabolism

Protecting effects of dexamethasone on thymus of rats with severe acute pancreatitis.

Dexamethasone megadoses stabilize rat liver lysosomal membranes by non-genomic and genomic effects

Biliary excretion of phenolphthalein sulfate in rats

Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats

Dexamethasone Changes the Pharmacokinetics of Amitriptyline and Reduces Its Accumulation in Rat Brain: the Roles of P-gp and Cyp3a2.

[Pharmacokinetics of Site-Specific Delivery of Dexamethasone-Dextran Prodrug in Rat Gastrointestinal Tract].

Effects of Chronic Dexamethasone Exposure on Bile Acid Metabolism and Cecal Epithelia Function in Goats.

Biliary excretion of bile acids and organic anions in rats with dichloroethylene-induced bile canalicular injury

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

Protective Effect of Dexamethasone on the Kidneys of Rats with Severe Acute Pancreatitis and its Mechanism.

Dexamethasone Suppresses the Expression of Multiple Rat Carboxylesterases Through Transcriptional Repression: Evidence for an Involvement of the Glucocorticoid Receptor

The effect of dexamethasone on L-alpha-lysophosphatidyl choline (lysolecithin)-induced demyelination of the rat spinal cord

Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats

Dexamethasone Upregulates the Expression of the Human SLC26A3 (DRA, Down-Regulated in Adenoma) Transporter (an IBD Susceptibility Gene) in Intestinal Epithelial Cells and Attenuates Gut Inflammation

Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats

Pharmacokinetics of colon-specific delivery of dexamethasone prodrug

The Effects of Probiotic Bacillus Spores on Dexamethasone-Treated Rats

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2